All Comments by Douglas Galasko
- End of the RoAD for Gantenerumab? Roche Declares Prodromal Alzheimer’s Trial Futile
- Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial.
- Characterization of Novel CSF Tau and ptau Biomarkers for Alzheimer's Disease.
- NIH Funds Prevention Trials and Translational Studies
- Cerebrospinal Fluid Tau Climbs in Aβ Mouse Models
- Development and advanced validation of an optimized method for the quantitation of aβ(42) in human cerebrospinal fluid.
- APOE {varepsilon}4 Status and Traumatic Brain Injury on the Gridiron or the Battlefield.
- In Mice, Oxidative Changes Come Early and Antioxidants Work
- Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses.
- Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology.
- Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift.
- Liver X receptor beta (LXRbeta): a link between beta-sitosterol and amyotrophic lateral sclerosis-Parkinson's dementia.
- Dementia screening in primary care: is it time?
- Glycation of the amyloid beta-protein by a nicotine metabolite: a fortuitous chemical dynamic between smoking and Alzheimer's disease.
- Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds.